Atara Biotherapeutics (ATRA) Income towards Parent Company (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Income towards Parent Company data on file, last reported at -$4.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 110.91% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.4 million (up 39.59% YoY) and the FY2025 annual result came in at $32.7 million, up 138.3% from the prior year.
• Income towards Parent Company declined to -$4.1 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
• A 5-year average of -$33.0 million and a median of -$21.9 million in 2024 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 485.08% — and 2025, when it jumped 219.71%.
• Tracing ATRA's Income towards Parent Company over 5 years: stood at -$74.6 million in 2022, then climbed by 18.94% to -$60.4 million in 2023, then jumped by 79.0% to -$12.7 million in 2024, then jumped by 73.31% to -$3.4 million in 2025, then dropped by 22.34% to -$4.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.